Country: Canada
Language: English
Source: Health Canada
TERAZOSIN (TERAZOSIN HYDROCHLORIDE); TERAZOSIN (TERAZOSIN HYDROCHLORIDE); TERAZOSIN (TERAZOSIN HYDROCHLORIDE)
ABBOTT LABORATORIES, LIMITED
G04CA03
TERAZOSIN
1MG; 2MG; 5MG
KIT
TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 1MG; TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 2MG; TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 5MG
ORAL
1 EA
Prescription
ALPHA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0336814001; AHFS:
CANCELLED POST MARKET
2006-10-17
_ _ _HYTRIN® Product Monograph _ _Page 1 of 37_ PRODUCT MONOGRAPH Pr HYTRIN ® terazosin hydrochloride 1, 2, 5 and 10 mg tablets Antihypertensive Agent Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH) Abbott Laboratories, Limited 8401 Trans-Canada Highway St. Laurent (Quebec) Canada H4S 1Z1 Date of Preparation: May 15, 1997 Date of Revision: June 15, 2006 Submission Control No: 104433 _ _ _HYTRIN® Product Monograph _ _Page 2 of 37_ Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS..................................................................................................10 DRUG INTERACTIONS ..................................................................................................14 DOSAGE AND ADMINISTRATION..............................................................................15 OVERDOSAGE ................................................................................................................16 ACTION AND CLINICAL PHARMACOLOGY ............................................................17 STORAGE AND STABILITY..........................................................................................19 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................19 PART II: SCIENTIFIC INFORMATION ...............................................................................20 PHARMACEUTICAL INFORMATION..........................................................................20 CLINICAL TRIALS..........................................................................................................21 DETAILED PHARMACOLOGY.................................... Read the complete document